In this episode of Virtually Live, Shannon Rivkin covers: Probiotec (PBP), Pacific Smiles Group (PSQ), Nick Scali (NCK) and more.
03:12 – Q1: – PBP, with FIRB approval being granted recently, are there any outstanding conditions remaining (other than shareholder approval)? Also, it mentions there is a permitted dividend of 4 cents which won’t affect the $3 Scheme Consideration payable. Do you think this dividend is likely?
10:17 – Q2:What are thoughts on the Nick Scali (NCK) capital raising Share Purchase Plan ? Do you think it is worth investing in ?
11:52 – Q3:Do you have any links to stat or charts that show the longterm performance of Australian EFTs ? And any advise thereto?